| [1] |
Melmed S. Pituitary-tumor endocrinopathies[J]. N Engl J Med, 2020, 382: 937-950.
|
| [2] |
Colao A, Grasso LFS, Giustina A, et al. Acromegaly[J]. Nat Rev Dis Primers, 2019, 5: 20.doi: 10.1038/s41572-41019-40071-41576.
|
| [3] |
Asa SL, Mete O, Perry A, et al. Overview of the 2022 WHO classification of pituitary tumors[J]. Endocr Pathol, 2022, 33: 6-26.
|
| [4] |
Obari A, Sano T, Ohyama K, et al. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form[J]. Endocr Pathol, 2008, 19: 82-91.
|
| [5] |
Yamato A, Nagano H, Gao Y, et al. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors[J]. Commun Biol, 2022, 5: 1304.doi: 1310.1038/s42003-42022-04272-42001.
|
| [6] |
VanInsberghe M, van den Berg J, Andersson-Rolf A, et al. Single-cell Ribo-seq reveals cell cycle-dependent translational pausing[J]. Nature, 2021, 597: 561-565.
|
| [7] |
Ben-Shlomo A, Deng N, Ding E, et al. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas[J]. J Clin Invest, 2020, 130: 5738-5755.
|
| [8] |
Zou Y, Bao X, Li D, et al. FTO-mediated DSP m(6)A demethylation promotes an aggressive subtype of growth hormone-secreting pituitary neuroendocrine tumors[J]. Mol Cancer, 2024, 23: 205.doi: 210.1186/s12943-12024-02117-12945.
|
| [9] |
Cai F, Chen S, Yu X, et al. Transcription factor GTF2B regulates AIP protein expression in growth hormone-secreting pituitary adenomas and influences tumor phenotypes[J]. Neuro Oncol, 2022, 24: 925-935.
|
| [10] |
Fabbri L, Chakraborty A, Robert C, et al. The plasticity of mRNA translation during cancer progression and therapy resistance[J]. Nat Rev Cancer, 2021, 21: 558-577.
|